Phio Pharmaceuticals Corp
For the period ended Jun 17, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 17, 2024 · Filed May 8, 2024
Use the contents to explore the available documents and sections.
Contents
Pay versus Performance
As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between the SEC-defined Compensation Actually Paid (“CAP”) to our NEO and certain of our financial performance metrics during the fiscal years listed below. The SEC-defined CAP data set forth in the table below does not necessarily reflect amounts actually paid, earned or received by our NEO, and the metrics are not those that the Compensation Committee uses when setting executive compensation.
The following table sets forth additional compensation information of our principal executive officer (“PEO”) along with total shareholder return and net income for our 2023 and 2022 fiscal years. The Company did not have any non-PEO NEO for fiscal years 2023 and 2022.
| Year | Summary Compensation Table Total for PEO (1) | CAP to PEO (2) | Value of Initial Fixed $100 Investment Based On Total Shareholder Return (3) | Net Income (Loss) (Thousands) |
|---|---|---|---|---|
| 2023 | $437,892 | $379,393 | $6.33 | $(10,826) |
| 2022 | $109,380 | $94,715 | $13.83 | $(11,480) |
| (1) | Mr. Bitterman has served as a member of the Company’s Board since 2012, served as the Company’s Interim Executive Chairman from September 2022 to February 2023 and was appointed as our President and Chief Executive Officer in February 2023. |
| (2) | CAP reflects the following exclusions and inclusions for the PEO in the table above: |
| Year | Summary Compensation Table Total | Minus: Grant Date Fair Value of Stock Awards and Option Awards from Summary Compensation Table | Plus: Year-end Fair Value of Unvested Equity Awards Granted During Year | Plus: Year-Over-Year Difference of Year-End Fair Value of Unvested Awards Granted in Prior Years | Plus: Fair Value at Vest Date for Awards Granted and Vested During Year | Plus: Year-Over-Year Difference of Year-End Fair Value of Prior Years’ Awards Vested During Year | Minus: Fair Value at Prior Year-end for Prior Years’ Awards that Fail to Meet Vesting Conditions During Year | Compensation Actually Paid |
|---|---|---|---|---|---|---|---|---|
| 2023 | $437,892 | $(57,640) | $8,360 | – | – | $(9,219) | – | $379,393 |
| 2022 | $109,380 | $(31,464) | $18,590 | – | – | $(1,791) | – | $94,715 |
| (3) | Total shareholder return as calculated based on a fixed investment of $100 measured from the market close on December 31, 2021 through and including the end of the fiscal year for each year reported in the table. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.